Ukraine is starting the summer campaign, and his pet mercenary warlord marched on Moscow.
Can MDMA cure racism? Scientists are looking into it.
This session’s rulings on voting rights have broken with recent trends.
It’s obvious how to make the roads safer for cyclists, pedestrians, and drivers alike. We just don’t do it.
So much energy is going into developing effective weight loss pills, while hundreds of lifesaving medications remain in shortage.
Today on TAP: The Wagner Group mutiny re-enacted aborted coups of yore.
In order to test whether improving people’s lives can convince them to support Democrats, you have to, well, improve people’s lives.
The U.S. trade representative is one of Biden’s most inspired appointees. She faces fierce resistance as she tries to carry out her president’s trade agenda.
Let’s compare his behavior to Justice Barrett.
Today on TAP: France could be the next country to elect a far-right president.
The Justice Department’s antitrust chief signaled that he would override banking regulators if necessary if a proposed merger harmed the public.
A new Oxfam survey on worker well-being compares us to the other advanced and semi-advanced economies. America remains exceptional-y bad.
Freight rail unions have gradually achieved their key demand from the labor dispute last year.
Labor groups fear offshore wind could go the same way as solar: low wages and temp workers.
Today on TAP: The Titan submersible tragedy has overshadowed the sinking of a boat carrying hundreds of impoverished migrants.
Before the Federal Trade Commission chair got there, the agency was brimming with conflicts of interest, including from her loudest critics.
An undercovered SCOTUS decision brushes against Native sovereign immunity, but also potentially snuffs out loopholes exploited by payday lenders.
In what has become a national battleground over public education, the campaign seeks to fundraise for and train progressive school board candidates.
Mark Rohrbaugh, a mid-level staffer at the National Institutes of Health, has consistently blocked the use of march-in rights to seize patents on high-cost drugs.
Today on TAP: Not if the state’s progressives and Democrats hope to be winning elections